Legal status by country
Is CT-868 legal?
Written by Aaron CuhaReviewed Sep 2026
How CT-868 is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Investigational, not approved | Investigational, not licensed | Investigational, not registered | Investigational, not approved |
| Note | Never approved. Roche discontinued development in July 2026, prioritising enicepatide, the once-weekly dual agonist from the same Carmot acquisition. | No filing; programme discontinued. | No filing; programme discontinued. | No filing; programme discontinued. |
US FDA status: Not approved. Development was discontinued by Roche in July 2026 after the phase 2 trial in type 2 diabetes.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.